Tarsa Therapeutics is a biopharmaceutical company developing an oral formulation of calcitonin for the treatment of osteoporosis. Calcitonin has a long history of safety and efficacy as an osteoporosis therapy but had only been available in injectable and intranasal formulations. Tarsa’s unique, once-daily calcitonin tablet has the potential to offer patients the proven safety and efficacy of calcitonin with the significant advantage of easier administration and enhanced long-term compliance. Tarsa’s oral calcitonin generated promising data in Phase II studies and patient enrollment in the global Phase III ORACAL trial was recently completed. Learn more »
Osteoporosis is a common but “silent” disease characterized by the loss of bone mass that leads to bone fragility and heightened risk of fractures. Osteoporosis affects an estimated 75 million people in the U.S., Europe and Japan and is an important cause of disability and loss of independence worldwide. Learn more >